Fig. 5
Immune infiltration prediction model predicts immune efficacy of immunotherapy vs five anti-tumor drugs. A–C Boxplots of IPTS between responder and non-responder groups in the validation set A GSE126044, B GSE135222, and C our independent LUSC cohort. The IPTS was significantly higher in the responder/benefit group than in the non-responder/no-benefit group; D–F ROC curve plot based on IPTS and immune response of patients in validation dataset D GSE126044, E GSE135222, and F our independent LUSC cohort; G, H survival curve plot according to IPTS, PFS time, and survival status of patients in the validation dataset G GSE135222 and H our independent LUSC cohort; I histogram based on IPTS molecular typing and the IC50 of five anti-tumor drugs; J heatmap based on IPTS molecular typing and the IC50 of five anti-tumor drugs. The IC50 of these drugs in the high score group was generally higher than in the low score group. *P < 0.05, **P < 0.01